Genomic Testing in Oncology to Improve Clinical Outcomes While Optimizing Utilization: the Evolution of Diagnostic Testing

Publishing Staff

Senior Vice President

of Operations and Clinical Affairs

Jeff D. Prescott, PharmD, RPh

Senior Clinical Projects Manager

Ida Delmendo

Clinical Projects Manager

Cindy Spielvogel

Project Manager

Jessica Toye

Proofreaders

Griselda DemasseyMaggie Shaw

Associate Editor

Jeanne Linke

Clinical Editor

Michael R. Page, PharmD, RPh

Designer

Julianne Costello

Associate Publisher

Justin T. Gallagher

Director of Sales

Sara Belanger

National Account Managers

Gabrielle ConsolaMichael Costella

Corporate

Chairman and CEO

Mike Hennessy, Sr

Vice Chairman

Jack Lepping

President

Mike Hennessy, Jr

Chief Operating Officer/CFO

Neil Glasser, CPA/CFE

President, Managed Markets, Pharmacy, and Rare Disease

Brian Haug

Executive Vice President

and General Manager

John Maglione

Chief Creative Officer

Jeff Brown

Human Resources Director

Shari Lundenberg

-PARTICIPATING FACULTY-

Faculty

David C. Collymore, MD, MBA

Chief Medical Officer

Acacia Network

New York, New York

Shaunna L. Kobilis, RN, BSN, OCN

Healthcare Consultant

Cleveland, Ohio

Thomas G. Lundquist, MD, MMM, FAAP, FACPE

Senior Vice President and Chief Medical Officer

Optima Health Plan

Sentara Health Plan

Virginia Beach, Virginia

William T. McGivney, PhD

Managing Principal

McGivney Global Advisors

King of Prussia, Pennsylvania

Edmund J. Pezalla, MD, MPH

Vice President and National Medical Director

Office of the Chief Medical Officer

Aetna

Hartford, Connecticut

Wendy Poage, MHA

President

Prostate and Men’s Health Education Councils

Centennial, Colorado

Administrator, Urologic Oncology

University of Colorado Medical Campus

Aurora, Colorado

Faculty Disclosures

These faculty report relationships with the following organizations:

William T. McGivney, PhD

Consultant or paid advisory board:

AbbVie, Aduro, Association of Community Cancer Centers,

bioTheranostics, Boston Biomedical, Bristol-Myers Squibb,

Eli Lilly, Foundation Medicine, Genentech, Genomic Health, Heron,

Novartis, and Taiho

Edmund J. Pezalla, MD, MPH

Employment:

Aetna

Wendy Poage, MHA

Consultant or paid advisory board:

MDx Health

Grant:

Genomic Health

David C. Collymore, MD, MBA; Shaunna L. Kobilis, RN, BSN, OCN

; and Thomas G. Lundquist, MD, MMM, FAAP, FACPE; have no relevant financial relationships with commercial interests to disclose.

Genomic Health, Inc.

This supplement was sponsored by

Participating faculty received an honorarium for their attendance at the roundtable meeting and for providing their perspectives.

Opinions expressed by authors, contributors, and advertisers are their own and not necessarily those of Clinical Care Targeted Communications, LLC, d/b/a Managed Care & Healthcare Communications, LLC, the editorial staff, or any member of the editorial advisory board. Clinical Care Targeted Communications, LLC, d/b/a Managed Care & Healthcare Communications, LLC, is not responsible for accuracy of dosages given in articles printed herein. The appearance of advertisements in this publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality, or safety. Clinical Care Targeted Communications, LLC, d/b/a Managed Care & Healthcare Communications, LLC, disclaims responsibility for any injury to persons or property resulting from any ideas or products referred to in the articles or advertisements.

Download PDF: Genomic Testing in Oncology to Improve Clinical Outcomes While Optimizing Utilization: the Evolution of Diagnostic Testing